{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T14:52:30Z","timestamp":1786978350919,"version":"build-2736575974"},"reference-count":48,"publisher":"Wiley","issue":"11","license":[{"start":{"date-parts":[[2025,4,24]],"date-time":"2025-04-24T00:00:00Z","timestamp":1745452800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["The Prostate"],"published-print":{"date-parts":[[2025,8]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Active surveillance (AS) is a recommended strategy for low\u2010 or favorable intermediate\u2010risk prostate cancers (PCa), avoiding more invasive treatments. However, the concurrent development of symptomatic benign prostatic hyperplasia (BPH) may necessitate holmium laser enucleation of the prostate (HoLEP). This study aims to evaluate the impact of HoLEP on patients under AS for PCa.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Medical records of patients under AS for PCa diagnosed between 2010 and 2023 were retrospectively reviewed. Patients with a life expectancy of more than 10 years and a follow\u2010up of at least 1 year were included. Functional and oncological outcomes, as well as follow\u2010up data (PSA levels, PSA density (PSA\u2010D), mpMRI, prostate biopsies), were collected. Patients who underwent HoLEP were compared to those who did not. The primary endpoint was discontinuation of AS.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      A total of 310 patients under AS were included, of whom 62 (20%) underwent HoLEP. Prostate volume was higher in the HoLEP group than in the non\u2010operated group (70 vs. 50\u2009g,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.0001), and PSA density was lower (0.09 vs. 0.12\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.0001). The median enucleated volume was 62\u2009mL (IQR 34\u201385). Grade group (GG) 1 and 2 prostate cancer was identified in enucleated pathology in 17 (27%) and 3 (5%) patients, respectively. No patient had a GG lesion \u2265\u20093 on the enucleated pathology. The rate of AS discontinuation was 18% in the HoLEP group vs. 56% in the control group (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.01). Multivariate analysis identified HoLEP as a protective factor for continued AS (HR\u2009=\u20090.231;\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.0001). At last follow\u2010up, PSA and PSA density were significantly lower in the HoLEP group (2 vs. 7.7\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.0001 and 0.06 vs. 0.14\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.0001, respectively).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Performing HoLEP in patients under AS for PCa with LUTS due to BPH may reduce the risk of deferred prostate cancer treatment, without altering oncological outcomes or future treatment options. HoLEP significantly impacts AS parameters, modifying patient monitoring. Further studies are needed to confirm these findings and establish appropriate follow\u2010up protocols.<\/jats:p>\n                    <jats:p>\n                      <jats:bold>Trial Registration:<\/jats:bold>\n                      CNIL number 24\u20105016\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1002\/pros.24906","type":"journal-article","created":{"date-parts":[[2025,4,25]],"date-time":"2025-04-25T01:45:20Z","timestamp":1745545520000},"page":"989-999","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Impact of Holmium Laser Enucleation of the Prostate on Active Surveillance for Prostate Cancer in Patients With Lower Urinary Tract Symptoms"],"prefix":"10.1002","volume":"85","author":[{"ORCID":"https:\/\/orcid.org\/0009-0002-7602-0377","authenticated-orcid":false,"given":"Charly","family":"B\u00e2cle","sequence":"first","affiliation":[{"name":"Urology Department CHU de la R\u00e9union, Site Sud \u2010 Avenue Fran\u00e7ois Mitterrand, 97448, Saint\u2010Pierre (La R\u00e9union)  Saint\u2010Pierre R\u00e9union"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2751-4111","authenticated-orcid":false,"given":"Emilien","family":"Seizilles De Mazancourt","sequence":"additional","affiliation":[{"name":"Urology Department Hospital Edouard Herriot, Hospices Civils de Lyon\u20145 place d'Arsonval Lyon France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nadia","family":"Abid","sequence":"additional","affiliation":[{"name":"Urology Department Hospital Edouard Herriot, Hospices Civils de Lyon\u20145 place d'Arsonval Lyon France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alain","family":"Ruffion","sequence":"additional","affiliation":[{"name":"Urology Department, Lyon Sud Hospital, Hospices Civils de Lyon, Lyon Cancer Innovation Center (EA 3738 CICLY) Lyon Sud Medical School, University of Lyon 1 Lyon France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olivier","family":"Rouvi\u00e8re","sequence":"additional","affiliation":[{"name":"D\u00e9partement d'Imagerie M\u00e9dicale et Interventionnelle Hospital Edouard Herriot, Hospices Civils de Lyon\u20145 place d'Arsonval Lyon France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marc","family":"Colombel","sequence":"additional","affiliation":[{"name":"Urology Department Hospital Edouard Herriot, Hospices Civils de Lyon\u20145 place d'Arsonval Lyon France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hakim","family":"Fassi\u2010Fehri","sequence":"additional","affiliation":[{"name":"Urology Department Hospital Edouard Herriot, Hospices Civils de Lyon\u20145 place d'Arsonval Lyon France"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2025,4,24]]},"reference":[{"key":"e_1_2_11_2_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.purol.2018.08.005"},{"key":"e_1_2_11_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2013.02.026"},{"key":"e_1_2_11_4_1","doi-asserted-by":"publisher","DOI":"10.1111\/bju.15286"},{"issue":"3","key":"e_1_2_11_5_1","article-title":"Lower Urinary Tract Symptoms in Patients With Prostate Cancer on Active Surveillance","volume":"206","author":"Jiang D. D.","year":"2021","journal-title":"Journal of Urology"},{"key":"e_1_2_11_6_1","unstructured":"E.Schaeffer S.Srinivas E. S.Antonarakis et al. \u201cNational Comprehensive Cancer Network (NCCN) Guidelines Version 2.2022 \u201d Prostate Cancer (NCCN 2021)."},{"key":"e_1_2_11_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2020.09.042"},{"key":"e_1_2_11_8_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1464-410X.2007.07341.x"},{"key":"e_1_2_11_9_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41585-022-00678-y"},{"issue":"5","key":"e_1_2_11_10_1","first-page":"87","article-title":"Holmium Laser Enucleation Versus Transurethral Resection of the Prostate: Results From a 2\u2010Center Prospective Randomized Trial in Patients With Obstructive Benign Prostatic Hyperplasia","volume":"179","author":"Montorsi F.","year":"2008","journal-title":"Journal of Urology"},{"key":"e_1_2_11_11_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1464-410X.2011.10359.x"},{"key":"e_1_2_11_12_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2007.04.053"},{"key":"e_1_2_11_13_1","doi-asserted-by":"publisher","DOI":"10.1159\/000200786"},{"key":"e_1_2_11_14_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2214122"},{"key":"e_1_2_11_15_1","doi-asserted-by":"publisher","DOI":"10.1089\/end.2022.0571"},{"key":"e_1_2_11_16_1","doi-asserted-by":"publisher","DOI":"10.3389\/fruro.2022.1018970"},{"issue":"4","key":"e_1_2_11_17_1","article-title":"Pd10\u201005\u2003Clinical and Pathologic Outcomes Following Holmium Laser Enucleation of the Prostate in Men Undergoing Active Surveillance for Prostate Cancer","volume":"201","author":"Charles N.","year":"2019","journal-title":"Journal of Urology"},{"key":"e_1_2_11_18_1","doi-asserted-by":"publisher","DOI":"10.1002\/pros.24433"},{"key":"e_1_2_11_19_1","doi-asserted-by":"publisher","DOI":"10.1097\/JU.0000000000003012"},{"key":"e_1_2_11_20_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.urolonc.2015.04.015"},{"key":"e_1_2_11_21_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2014.06.010"},{"key":"e_1_2_11_22_1","doi-asserted-by":"publisher","DOI":"10.1097\/JU.0000000000001903"},{"key":"e_1_2_11_23_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2020.3187"},{"key":"e_1_2_11_24_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.urolonc.2020.11.003"},{"key":"e_1_2_11_25_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.urology.2009.06.039"},{"key":"e_1_2_11_26_1","doi-asserted-by":"publisher","DOI":"10.1097\/JU.0000000000000530"},{"key":"e_1_2_11_27_1","doi-asserted-by":"publisher","DOI":"10.1111\/iju.15315"},{"key":"e_1_2_11_28_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00345-020-03518-z"},{"key":"e_1_2_11_29_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12894-019-0523-z"},{"key":"e_1_2_11_30_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11255-022-03351-w"},{"key":"e_1_2_11_31_1","doi-asserted-by":"publisher","DOI":"10.1089\/end.2014.0009"},{"key":"e_1_2_11_32_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2021.05.001"},{"key":"e_1_2_11_33_1","doi-asserted-by":"publisher","DOI":"10.1002\/pros.24771"},{"key":"e_1_2_11_34_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1464-410x.2000.00380.x"},{"key":"e_1_2_11_35_1","doi-asserted-by":"publisher","DOI":"10.3389\/fsurg.2021.726534"},{"key":"e_1_2_11_36_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00432-018-2597-5"},{"key":"e_1_2_11_37_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10103-019-02913-2"},{"key":"e_1_2_11_38_1","doi-asserted-by":"publisher","DOI":"10.1007\/s13691-018-0324-3"},{"key":"e_1_2_11_39_1","doi-asserted-by":"publisher","DOI":"10.1111\/iju.12248"},{"issue":"6","key":"e_1_2_11_40_1","first-page":"605","article-title":"Favorable Long\u2010Term Oncological and Urinary Outcomes of Incidental Prostate Cancer Following Holmium Laser Enucleation of the Prostate","volume":"10","author":"Tominaga Y.","year":"2019","journal-title":"Molecular and Clinical Oncology"},{"key":"e_1_2_11_41_1","doi-asserted-by":"publisher","DOI":"10.1097\/JU.0000000000000312"},{"key":"e_1_2_11_42_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00345-019-02986-2"},{"key":"e_1_2_11_43_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.euf.2020.09.003"},{"key":"e_1_2_11_44_1","doi-asserted-by":"publisher","DOI":"10.1089\/end.2014.0767"},{"key":"e_1_2_11_45_1","doi-asserted-by":"publisher","DOI":"10.1089\/end.2019.0436"},{"key":"e_1_2_11_46_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.prnil.2016.01.001"},{"key":"e_1_2_11_47_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.urolonc.2024.04.022"},{"key":"e_1_2_11_48_1","doi-asserted-by":"publisher","DOI":"10.1002\/cnr2.1672"},{"key":"e_1_2_11_49_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00345-024-05220-w"}],"container-title":["The Prostate"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/pros.24906","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T08:25:49Z","timestamp":1751358349000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/pros.24906"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,24]]},"references-count":48,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2025,8]]}},"alternative-id":["10.1002\/pros.24906"],"URL":"https:\/\/doi.org\/10.1002\/pros.24906","archive":["Portico"],"relation":{},"ISSN":["0270-4137","1097-0045"],"issn-type":[{"value":"0270-4137","type":"print"},{"value":"1097-0045","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4,24]]},"assertion":[{"value":"2024-11-11","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-04-14","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-04-24","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}